ATE333896T1 - Vaskularisierungsinhibitoren - Google Patents

Vaskularisierungsinhibitoren

Info

Publication number
ATE333896T1
ATE333896T1 AT99909307T AT99909307T ATE333896T1 AT E333896 T1 ATE333896 T1 AT E333896T1 AT 99909307 T AT99909307 T AT 99909307T AT 99909307 T AT99909307 T AT 99909307T AT E333896 T1 ATE333896 T1 AT E333896T1
Authority
AT
Austria
Prior art keywords
vascularization inhibitors
vascularization
inhibitors
cxcr
potentiates
Prior art date
Application number
AT99909307T
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Takashi Nagasawa
Kazunobu Tachibana
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14137987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE333896(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE333896T1 publication Critical patent/ATE333896T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT99909307T 1998-03-24 1999-03-23 Vaskularisierungsinhibitoren ATE333896T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9544898 1998-03-24

Publications (1)

Publication Number Publication Date
ATE333896T1 true ATE333896T1 (de) 2006-08-15

Family

ID=14137987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99909307T ATE333896T1 (de) 1998-03-24 1999-03-23 Vaskularisierungsinhibitoren

Country Status (8)

Country Link
US (2) US8119126B2 (de)
EP (4) EP1745797A3 (de)
JP (2) JP4974408B2 (de)
AT (1) ATE333896T1 (de)
AU (1) AU2855399A (de)
DE (1) DE69932510T2 (de)
ES (2) ES2525669T3 (de)
WO (1) WO1999048528A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6863887B1 (en) 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
AU766675B2 (en) 1998-03-30 2003-10-23 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
ATE428706T1 (de) * 1999-12-17 2009-05-15 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
US20090291087A1 (en) * 2002-03-21 2009-11-26 University Of Florida Research Foundation, Inc. Modulating angiogenesis
US7491389B2 (en) * 2002-03-21 2009-02-17 University Of Florida Reasearch Foundation, Inc. Modulating angiogenesis
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
JP2009531283A (ja) * 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
MX2009000656A (es) 2006-07-18 2009-03-25 Noxxon Pharma Ag Acidos nucleicos que se fijan a sdf-i.
CN101796188B (zh) * 2007-08-06 2014-10-29 诺松制药股份公司 Sdf-1结合核酸及其用途
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
CA2749026C (en) 2008-09-29 2018-01-09 Impala, Inc. Heart valve
EP2341871B1 (de) 2008-10-01 2017-03-22 Edwards Lifesciences CardiAQ LLC Abgabesystem für ein gefässimplantat
AU2010236288A1 (en) 2009-04-15 2011-10-20 Cardiaq Valve Technologies, Inc. Vascular implant and delivery system
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
DK2613789T3 (en) 2010-09-09 2018-07-23 Noxxon Pharma Ag SDF-1-binding nucleic acids and their use in cancer treatment
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
US10583002B2 (en) 2013-03-11 2020-03-10 Neovasc Tiara Inc. Prosthetic valve with anti-pivoting mechanism
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
JP2016224834A (ja) * 2015-06-03 2016-12-28 キヤノン株式会社 電子機器、その制御方法
CN117357649A (zh) * 2023-11-15 2024-01-09 天津医科大学总医院 基于cd8+t淋巴细胞的免疫疗法在新生血管性眼病中的应用
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3135616B2 (ja) 1990-07-30 2001-02-19 武田薬品工業株式会社 血管新生阻害剤
JPH04224559A (ja) 1990-12-26 1992-08-13 Fujisawa Pharmaceut Co Ltd 血管新生阻害物質　ｆｒ−９０１４４８　およびｆｒ−９０１４４９
US5543503A (en) * 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
EP0666868B2 (de) 1992-10-28 2006-06-14 Genentech, Inc. Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
JP3367581B2 (ja) * 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
WO1996024598A1 (en) 1995-02-10 1996-08-15 The University Of British Columbia [4-hexadecyl-3-methoxy-butyl] phosphonic acid and its protein conjugates useful as anti-cancer agents
US6197578B1 (en) * 1996-01-30 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Cells expressing both human CD4 and a human fusion accessory factor associated with HIV infection
EP0897980A3 (de) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: Eine menschliche Spleissvariante des CXCR4 Chemokinrezeptors
US6863887B1 (en) * 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

Also Published As

Publication number Publication date
DE69932510T2 (de) 2007-02-15
EP1072273A4 (de) 2004-04-28
EP1072273A1 (de) 2001-01-31
JP2009256359A (ja) 2009-11-05
US20130236889A1 (en) 2013-09-12
JP5285513B2 (ja) 2013-09-11
EP1745797A3 (de) 2007-07-18
ES2525669T3 (es) 2014-12-29
AU2855399A (en) 1999-10-18
EP2311495B1 (de) 2014-09-24
JP4974408B2 (ja) 2012-07-11
EP2108377A1 (de) 2009-10-14
US8119126B2 (en) 2012-02-21
EP2311495A1 (de) 2011-04-20
US20040209837A1 (en) 2004-10-21
EP1745797A2 (de) 2007-01-24
ES2268854T3 (es) 2007-03-16
EP1072273B1 (de) 2006-07-26
DE69932510D1 (de) 2006-09-07
WO1999048528A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
ATE333896T1 (de) Vaskularisierungsinhibitoren
BR0107565A (pt) Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
TR199801315T2 (xx) X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�.
MY129356A (en) Electrospun pharmaceutical compositions
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
SE9404196D0 (sv) New antithrombotic formulation
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
PT866870E (pt) Proteinas de fusao factor tecidual-dominio de kunitz como inibidores do factor viia
FR2765483B1 (fr) Medicament destine a traiter les dysfonctions erectiles
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
ITRM950273A0 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni farmaceutiche.
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties